About tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A
tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A (TRMT61A) is a protein
from Homo sapiens identified by UniProt accession
Q96FX7, 289 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A |
|---|
| UniProt accession | Q96FX7 |
|---|
| Gene | TRMT61A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 289 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (76)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- reticulocyte count · score 0.23
- reticulocyte measurement · score 0.19
- vitamin D measurement · score 0.13
- intelligence · score 0.11
- hemoglobin measurement · score 0.11
- erythrocyte count · score 0.11
- pancreatic carcinoma · score 0.10
- mean corpuscular volume · score 0.10
- red blood cell density measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96FX7-F1 | alphafold | PREDICTED | 92.28 | — |
Amino-acid sequence (289 residues)
MSFVAYEELI KEGDTAILSL GHGAMVAVRV QRGAQTQTRH GVLRHSVDLI GRPFGSKVTC GRGGWVYVLH PTPELWTLNL PHRTQILYST DIALITMMLE LRPGSVVCES GTGSGSVSHA IIRTIAPTGH LHTVEFHQQR AEKAREEFQE HRVGRWVTVR TQDVCRSGFG VSHVADAVFL DIPSPWEAVG HAWDALKVEG GRFCSFSPCI EQVQRTCQAL AARGFSELST LEVLPQVYNV RTVSLPPPDL GTGTDGPAGS DTSPFRSGTP MKEAVGHTGY LTFATKTPG
Explore tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets